In a dramatic reversal of fortune, Hims & Hers Health (NYSE:HIMS) has been rescued by the very company that nearly sank it. Novo Nordisk (NYSE:NVO | NVO Price Prediction), which sued the telehealth provider just last month over copycat compounded GLP-1 drugs, has now agreed to partner with Hims to sell its branded obesity medications — including Wegovy and Ozempic — directly through the platform. The deal is expected to be announced as soon as Monday, ending the bitter legal feud and restoring a critical revenue stream that Hims had lost when their initial collaboration collapsed last year.
Hims shares surged about 40% in aftermarket trading, erasing months of pain and signaling Wall Street’s relief that the company’s growth engine is back online. What looked like a slow death by regulatory pressure and lost momentum has suddenly become a second act. Novo Nordisk, once Hims’ aggressor, is now its savior.
From Boom to Bust
Hims & Hers rose like a rocket during the telehealth boom. What began as a platform for hair-loss treatments, erectile dysfunction meds, and skincare evolved into a weight-loss powerhouse once GLP-1 agonists exploded in popularity. During the acute shortage of Wegovy and Ozempic in 2023–2024, Hims capitalized by offering compounded semaglutide versions at lower prices and faster delivery. New customers flooded in, subscriptions soared, and the stock hit all-time highs nearly a year ago as investors bet on endless demand for obesity drugs.
That bet unraveled fast. As the FDA declared the semaglutide shortage over, Novo Nordisk turned hostile. Last April’s partnership to expand Wegovy access via telehealth lasted only until June, when Novo abruptly terminated the deal, citing safety concerns over Hims’ compounded products. The real hammer came last month: Novo sued for patent infringement after Hims launched a $49 compounded oral pill mimicking Novo’s new formulation. Hims pulled the product under FDA pressure.
Compounding the damage were parallel regulatory clouds — an SEC investigation into Hims’ marketing practices and whispers of a potential Justice Dept. probe into the safety and legality of compounded GLP-1s. Investors fled. From its peak, the stock cratered 77%, wiping out billions in market value and leaving Hims staring at a future of slowed growth and limited upside without the GLP-1 tailwind.
Novo Nordisk’s Fight to Reclaim GLP-1 Supremacy
For Novo Nordisk, the partnership is more than damage control — it’s a strategic alliance. Eli Lilly’s (NYSE:LLY) Zepbound has been stealing market share with superior efficacy data and aggressive marketing. Novo’s response includes its new oral obesity pill, designed to broaden access and reduce injection fatigue. Distributing branded versions through Hims’ massive telehealth audience gives Novo instant scale without building its own direct-to-consumer infrastructure.
Yet the move carries risks for both sides. Novo regains control over its brand and pricing, but it must now share the customer relationship with a former rival. Hims, meanwhile, regains a high-margin product line that once drove explosive customer acquisition.
However, the partnership is not without peril for Hims. This is the second time the companies have danced — only for Novo to walk away when it suited its interests. The June termination triggered an immediate stock crash and forced Hims to scramble for alternatives. Now fully reliant on Novo for its flagship growth driver, Hims risks the same fate again if regulatory winds shift, supply tightens, or Novo decides to tighten distribution.
Hims has diversified into heart health, mental wellness, and dermatology, but none match the customer-drawing power of GLP-1s. The platform’s future once again hinges on one partner’s goodwill.
Key Takeaways
For Novo Nordisk, aligning with Hims is a smart piece of its comeback playbook. With government pressure already pushing GLP-1 prices lower, partnering with a low-cost telehealth distributor lets Novo reach millions more patients without sacrificing the premium margins that compounded knockoffs once threatened. It’s a controlled way to flood the market while keeping profits in-house.
For Hims & Hers, this lifeline is transformative. GLP-1s weren’t just a product — they were the on-ramp that pulled new users into the broader ecosystem of personalized therapies. While the company offers treatments for everything from hair loss to sexual health, obesity drugs remain the single biggest growth engine. Restoring branded access stabilizes revenue, rebuilds investor trust, and buys time to prove the platform can thrive beyond any single supplier.
The reversal is real, but so is the risk. Hims has survived the bust; now it must navigate the boom without repeating the same dangerous dependence.
Top Gaining Stocks
Top Losing Stocks